Astellas Pharma plunked down $1.4 billion to acquire Ganymed Pharmaceuticals and its experimental pipeline asset IMAB362 as a first-line treatment in gastric cancer.

Following a disappointing review of interim data from a clinical study of GS-5745, an investigational anti-MMP9 antibody, Gilead said the company will halt the trial.

ImmunoGen Inc said the gastric cancer drug it is developing with Roche Holding AG did not meet the main goal in a large study. ImmunoGen entered into a royalty purchase agreement with Roche for Kadcyla this year. Kadcyla, approved in 2013 for the treatment of late-stage breast cancer, was being tested as a second-line treatment […]

A new report finds that taking antibiotics for a common bacteria, Helicobacter pylori, reduces the occurrence of gastric cancer. For decades, doctors have understood that H. pylori infection plays a role in malignancy of the stomach. In infected adults, a brief course of antibiotics lessens cancer risk. But the analysis, published by the Cochrane Library, did not show that […]